Condition: Pancreatic Cancer · Sponsor: Shandong Suncadia Medicine Co., Ltd.
This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.
This description comes directly from the study's public registry record.
Meng Qin · +0518-81220121 · meng.qin.mq8@hengrui.com
Keke Yan · +0518-81220121 · keke.yan@hengrui.com
Always discuss trial participation with your own doctor first.
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07589569